BioSpaceOriginal article
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
Phase 3positivePositive
AI Analysis
Summary
GSK and Hansoh Pharmaceutical's antibody-drug conjugate achieved success in late-stage development, positioning the program for regulatory submission in China. The positive trial outcome validates the Big Pharma-China biotech partnership model for oncology candidates.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Late-stage ADC study success
Importance:7/10
Sentiment:
0.75
antibody-drug conjugateoncologyChinapartnershipregulatory submission
Read the original article
Published by BioSpace on July 10, 2026 2:03 PM